Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial.

Helfand BT, Lee JY, Sharp V, Foster H, Naslund M, Williams OD, McVary KT; CAMUS Study Group.

J Urol. 2012 Dec;188(6):2288-93. doi: 10.1016/j.juro.2012.07.104. Epub 2012 Oct 22.

PMID:
23083656
2.

The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial.

Helfand BT, McVary KT, Meleth S, Sharp V, Foster H, Naslund M, Williams OD; CAMUS Study Group.

J Urol. 2011 Jun;185(6):2223-8. doi: 10.1016/j.juro.2011.02.012. Epub 2011 Apr 17.

PMID:
21497839
3.

Serenoa repens for benign prostatic hyperplasia.

Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD001423. doi: 10.1002/14651858.CD001423.pub3. Review.

PMID:
23235581
4.

Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.

MacDonald R, Tacklind JW, Rutks I, Wilt TJ.

BJU Int. 2012 Jun;109(12):1756-61. doi: 10.1111/j.1464-410X.2012.11172.x. Epub 2012 May 2. Review.

5.

Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.

Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE Jr, Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT; Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group.

JAMA. 2011 Sep 28;306(12):1344-51. doi: 10.1001/jama.2011.1364. Erratum in: JAMA. 2012 Jun 13;307(22):2374.

6.

Serenoa repens for benign prostatic hyperplasia.

Wilt T, Ishani A, Mac Donald R.

Cochrane Database Syst Rev. 2002;(3):CD001423. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001423.

PMID:
12137626
7.

Phytotherapy for benign prostatic hyperplasia.

Wilt TJ, Ishani A, Rutks I, MacDonald R.

Public Health Nutr. 2000 Dec;3(4A):459-72.

PMID:
11276294
8.

Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia.

Lee J, Andriole G, Avins A, Crawford ED, Foster H, Kaplan S, Kreder K, Kusek J, McCullough A, McVary K, Meleth S, Naslund M, Nickel JC, Nyberg L, Roehrborn C, Dale Williams O, Barry M.

Clin Trials. 2009 Dec;6(6):628-36. doi: 10.1177/1740774509352199. Epub 2009 Dec 9.

9.
10.

An improvement in sexual function is related to better quality of life, regardless of urinary function improvement: results from the IDIProst® Gold Study.

Cai T, Morgia G, Carrieri G, Terrone C, Imbimbo C, Verze P, Mirone V; IDIProst® Gold Study Group.

Arch Ital Urol Androl. 2013 Dec 31;85(4):184-9. doi: 10.4081/aiua.2013.4.184.

11.

Impact of phytotherapy on utility scores for 5 benign prostatic hyperplasia/lower urinary tract symptoms health states.

Dedhia RC, Calhoun E, McVary KT.

J Urol. 2008 Jan;179(1):220-5. Epub 2007 Nov 14.

PMID:
18001791
12.

Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia.

Lee JY, Foster HE Jr, McVary KT, Meleth S, Stavris K, Downey J, Kusek JW.

J Altern Complement Med. 2011 May;17(5):469-72. doi: 10.1089/acm.2010.0300. Epub 2011 May 9.

13.

Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.

Bertaccini A, Giampaoli M, Cividini R, Gattoni GL, Sanseverino R, Realfonso T, Napodano G, Fandella A, Guidoni E, Prezioso D, Galasso R, Cicalese C, Scattoni V, Armenio A, Conti G, Corinti M, Spasciani R, Liguori G, Lampropoulou N, Martorana G.

Arch Ital Urol Androl. 2012 Sep;84(3):117-22.

PMID:
23210402
14.

Saw palmetto for benign prostatic hyperplasia.

Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins AL.

N Engl J Med. 2006 Feb 9;354(6):557-66.

15.

Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.

Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C.

JAMA. 1998 Nov 11;280(18):1604-9. Erratum in: JAMA 1999 Feb 10;281(6):515.

PMID:
9820264
16.

Safety and toxicity of saw palmetto in the CAMUS trial.

Avins AL, Lee JY, Meyers CM, Barry MJ; CAMUS Study Group.

J Urol. 2013 Apr;189(4):1415-20. doi: 10.1016/j.juro.2012.10.002. Epub 2012 Oct 9.

17.

Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms.

Gerber GS, Kuznetsov D, Johnson BC, Burstein JD.

Urology. 2001 Dec;58(6):960-4; discussion 964-5.

PMID:
11744467
18.

Performance of the American Urological Association Symptom Index with and without an additional urge incontinence item.

Barry MJ, Avins AL, Meleth S; Complementary and Alternative Medicine for Urological Symptoms Study Group.

Urology. 2011 Sep;78(3):550-4. doi: 10.1016/j.urology.2011.04.017. Epub 2011 Jul 8.

19.

LUTS and sleep disorders: emerging risk factor.

Cakir OO, McVary KT.

Curr Urol Rep. 2012 Dec;13(6):407-12. doi: 10.1007/s11934-012-0281-x. Review.

PMID:
23076504
20.

Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.

Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S.

J Urol. 2013 Jan;189(1 Suppl):S135-40. doi: 10.1016/j.juro.2012.11.025.

PMID:
23234619
Items per page

Supplemental Content

Write to the Help Desk